Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7833990 | 0.91 | PPARG (0.57) | PPARGFFAR1PPARA | |
| SCHEMBL7822745 | 0.78 | KDM4E (0.53) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8314978 | 0.77 | FFAR1 (0.70) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL1299855 | 0.77 | FFAR1 (0.80) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL8312136 | 0.76 | FFAR1 (0.87) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL7454600 | 0.76 | FFAR1 (0.62) | PPARGFFAR1PPARA | |
| SCHEMBL10365333 | 0.74 | FFAR1 (0.63) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL1072226 | 0.74 | FFAR1 (0.77) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL9570853 | 0.74 | FFAR1 (0.69) | PPARGFFAR1PPARAALDH1A1 | |
| SCHEMBL8957444 | 0.74 | FFAR1 (0.69) | PPARGFFAR1PPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |